<?xml version="1.0" encoding="UTF-8"?>
<ref id="pone.0074027-Afdahl1">
 <label>33</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Afdahl</surname>
   <given-names>N</given-names>
  </name>, 
  <name>
   <surname>Godofsky</surname>
   <given-names>E</given-names>
  </name>, 
  <name>
   <surname>Dienstag</surname>
   <given-names>J</given-names>
  </name>, 
  <name>
   <surname>Rustgi</surname>
   <given-names>V</given-names>
  </name>, 
  <name>
   <surname>Schick</surname>
   <given-names>L</given-names>
  </name>, 
  <etal>et al</etal> (
  <year>2004</year>) 
  <article-title>Final phase I/II trial results for NM283, a new polymerease inhibitor for hepatitits C: antiviral efficacy and tolerance in patients with HCV-1 infection, including revious interferon failures</article-title>. 
  <source>55th AnnualMeeting of the American Association for the Study of LiverDiseases October 29-November 2; Boston, Massachusetts</source>
  <volume>2004</volume>: 
  <fpage>726A</fpage>.
 </mixed-citation>
</ref>
